Pylotrip R20 mg+500 mg+1000 mg

Pylotrip R is a co-packaged fixed combination (proton pump inhibitor plus two antibiotics) indicated for the eradication of Helicobacter pylori (H. pylori) infection, typically prescribed together with confirmed or strongly suspected active or past peptic ulcer disease (gastric or duodenal ulcer). Its use is classified below by strength of evidence:

• Established/guideline-supported use: First-line triple therapy for H. pylori eradication in patients with peptic ulcer disease, in regions/populations with low clarithromycin resistance, per international consensus guidelines (e.g., ACG, Maastricht/Florence consensus, WHO-aligned national guidance).
• Combination-dependent use: Each component alone is insufficient for eradication; Pylotrip R works only as the complete three-drug regimen taken together — omitting or substituting any one component reduces eradication rates and promotes antibiotic resistance.
• Adjunct rationale: The rabeprazole component raises intragastric pH, which improves the antibacterial activity and stability of amoxicillin and clarithromycin and also promotes ulcer healing during therapy.

Pylotrip R is not intended for use as acid-suppression monotherapy, for uninvestigated dyspepsia without confirmed H. pylori infection, or for treatment of infections other than H. pylori.

Rabeprazole + Amoxicillin + Clarithromycin is supplied as a co-packaged combination (kit/blister pack) containing three separate medicines to be taken together at each dosing time:

• Rabeprazole (as rabeprazole sodium) — typically 20 mg per delayed-release tablet, a proton pump inhibitor.
• Amoxicillin (as amoxicillin trihydrate) — typically 1000 mg per capsule/tablet, an aminopenicillin antibiotic.
• Clarithromycin — typically 500 mg per tablet, a macrolide antibiotic.

Exact strengths and pack configuration may vary by manufacturer; the prescribing physician's instructions and the product label should always be followed.

Pylotrip R is a fixed triple-therapy regimen combining a proton pump inhibitor with two antibiotics, co-packaged for the specific purpose of eradicating Helicobacter pylori infection of the stomach, a major cause of peptic ulcer disease and a recognized risk factor for gastric cancer. Rabeprazole suppresses gastric acid secretion, creating an environment that supports ulcer healing and enhances antibiotic activity, while amoxicillin and clarithromycin act together to kill H. pylori bacteria. All three components of Pylotrip R must be taken together, at the prescribed doses and for the full prescribed duration, to achieve successful eradication and to reduce the risk of antibiotic resistance.

Pylotrip R is a fixed combination/co-packaged triple-therapy anti-Helicobacter pylori regimen consisting of a Proton Pump Inhibitor (rabeprazole) together with an Aminopenicillin Antibiotic (amoxicillin) and a Macrolide Antibiotic (clarithromycin).

Mechanism of Action

Rabeprazole + Amoxicillin + Clarithromycin combines three complementary mechanisms:

• Rabeprazole: Irreversibly inhibits the H±/K±-ATPase (proton pump) in gastric parietal cells, profoundly suppressing gastric acid secretion. Reduced acidity promotes ulcer healing and improves the stability and antibacterial efficacy of the co-administered antibiotics.
• Amoxicillin: A beta-lactam antibiotic that inhibits bacterial cell-wall synthesis by binding penicillin-binding proteins, leading to bacterial cell lysis and death; active against H. pylori.
• Clarithromycin: A macrolide antibiotic that binds the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth; a key agent against H. pylori, though efficacy is reduced by rising clarithromycin resistance in some regions.

Pharmacokinetics (summary)

• Rabeprazole: Acid-labile, given as an enteric-coated/delayed-release tablet; metabolized mainly non-enzymatically and via hepatic CYP3A4/CYP2C19; short plasma half-life but prolonged duration of acid suppression due to irreversible enzyme binding.
• Amoxicillin: Well absorbed orally, largely excreted unchanged by the kidneys; requires dose adjustment in significant renal impairment.
• Clarithromycin: Metabolized hepatically via CYP3A4 to an active metabolite; eliminated both renally and hepatically; a potent CYP3A4 inhibitor, which underlies its major drug interactions.

All three components of Pylotrip R should be taken together, twice daily (approximately every 12 hours), generally shortly before a meal. Tablets and capsules should be swallowed whole with a full glass of water and should not be crushed or chewed unless the product labeling specifically permits it. Pylotrip R should be taken at around the same times each day to maintain consistent drug levels, and the complete course must be finished even if symptoms improve before the course ends.

Pylotrip R (via its clarithromycin and, to a lesser extent, rabeprazole components) is associated with several well-established, clinically significant interactions:

Patients should inform their physician of all other medicines, supplements, and herbal products before starting Pylotrip R, particularly the interactions above requiring a medication review.

Common side effects reported with Pylotrip R include:

• Diarrhea, loose stools, nausea, abdominal pain
• Taste disturbance (metallic/bitter taste, common with clarithromycin)
• Headache
• Vaginal candidiasis or oral thrush (antibiotic-related)

Less common but serious effects requiring prompt medical attention:

• Clostridioides difficile-associated diarrhea/colitis, which can range from mild to life-threatening and may occur during or up to several weeks after therapy
• Severe allergic reactions, including rash, urticaria, angioedema, or anaphylaxis (amoxicillin)
• QT-interval prolongation and, rarely, serious ventricular arrhythmia (clarithromycin)
• Hepatotoxicity/abnormal liver function, including rare cholestatic jaundice
• Severe cutaneous reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) – rare

Patients should seek immediate medical attention for severe or persistent diarrhea, signs of an allergic reaction, palpitations/fainting, or yellowing of the skin or eyes while taking Pylotrip R.

Pregnancy: Pylotrip R should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Amoxicillin is generally considered to have a well-established safety profile in pregnancy when indicated, but clarithromycin and rabeprazole have more limited pregnancy safety data, and clarithromycin in particular should be avoided unless no safer alternative antibiotic is suitable. A physician must weigh the risks and benefits and, where possible, consider alternative eradication regimens in pregnant patients.

Lactation: All three components of Pylotrip R pass into breast milk in small amounts. Pylotrip R should be used during breastfeeding only on a physician's advice, with the infant monitored for diarrhea, thrush, or allergic-type reactions.

• Antibiotic stewardship: Take Pylotrip R exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice. Completing the full prescribed course, even after symptoms improve, is essential for successful H. pylori eradication and to reduce the development of antibiotic resistance.
• Clostridioides difficile-associated diarrhea: Can occur with either antibiotic component, ranging from mild diarrhea to severe colitis; seek medical advice for severe, persistent, or bloody diarrhea, including after completing the course.
• QT prolongation: The clarithromycin component carries a risk of QT-interval prolongation; use with caution in patients with cardiac disease, electrolyte abnormalities (hypokalemia, hypomagnesemia), or other QT-prolonging drugs (see Interactions/Contraindications).
• Hypersensitivity/rash: Amoxicillin can cause allergic reactions ranging from mild rash to anaphylaxis; a rash occurring during antibiotic use in a patient with an underlying viral illness may be a non-allergic viral exanthem, but any new rash should be evaluated by a physician before continuing therapy.
• Confirm eradication: Physicians typically confirm successful H. pylori eradication with an appropriate test (e.g., urea breath test or stool antigen test) performed at least 4 weeks after completing Pylotrip R, following standard practice.
• Not for acid-suppression monotherapy: Pylotrip R is a combination antimicrobial eradication regimen and is not intended to be used, or its components used alone, simply for acid-related symptom relief.
• Superinfection: Prolonged antibiotic use may result in overgrowth of non-susceptible organisms, including fungal infection.

Overdose of Pylotrip R may cause exaggerated gastrointestinal effects (severe nausea, vomiting, diarrhea, abdominal pain), and in severe cases, effects related to the individual components such as electrolyte disturbance, cardiac rhythm changes, or crystalluria. There is no specific antidote. If an overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services right away; treatment is supportive and symptom-directed under medical supervision.

Store Pylotrip R at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use beyond the expiry date printed on the pack.

Renal Impairment

No dose adjustment of rabeprazole is generally needed. The amoxicillin dosing interval should be adjusted in patients with significant renal impairment (e.g., creatinine clearance below 30 mL/min), per physician judgment. Clarithromycin dose/frequency may also need reduction in severe renal impairment. Colchicine co-administration is contraindicated in renal impairment (see Contraindications).

Hepatic Impairment

Pylotrip R should be used with caution in mild-to-moderate hepatic impairment and is contraindicated in severe hepatic impairment (see Contraindications).

Elderly

No specific dose adjustment is generally required based on age alone, but elderly patients may be at higher risk of QT prolongation, renal impairment, and C. difficile-associated diarrhea, warranting closer monitoring.

Pediatric Use

See Pediatric Uses section.

Pregnancy and Lactation

See Pregnancy and Lactation section.

The typical course of Pylotrip R for H. pylori eradication lasts 7 to 14 days, with many current treatment guidelines favoring 14-day courses to maximize eradication rates, depending on local antibiotic resistance patterns and physician judgment. The complete prescribed duration must be finished even if symptoms resolve earlier; stopping early risks treatment failure and antibiotic resistance.

Proton Pump Inhibitor (Rabeprazole) + Aminopenicillin Antibiotic (Amoxicillin) + Macrolide Antibiotic (Clarithromycin) – fixed combination anti-Helicobacter pylori triple therapy.

Rabeprazole + Amoxicillin + Clarithromycin works through three complementary actions taken together: rabeprazole profoundly and durably suppresses gastric acid secretion by irreversibly inhibiting the parietal cell proton pump, which both promotes healing of the gastric/duodenal mucosa and creates conditions that enhance antibiotic activity against Helicobacter pylori; amoxicillin kills actively dividing H. pylori bacteria by inhibiting bacterial cell-wall synthesis; and clarithromycin inhibits bacterial protein synthesis at the ribosomal level, providing a second, complementary antibacterial mechanism. Using all three agents together reduces the likelihood that resistant bacteria will survive and allows successful eradication of the infection.

Not formally assigned as a fixed-combination product. Individual legacy FDA pregnancy categories: Amoxicillin - B; Clarithromycin - C; Rabeprazole - B.

Safety and efficacy of Pylotrip R as a fixed triple-therapy combination have not been established in pediatric patients. Where H. pylori eradication therapy is required in children, it is generally undertaken using individually selected, weight-based dosing of a proton pump inhibitor and appropriate antibiotics under the supervision of a pediatric gastroenterology specialist, rather than this adult-dose combination pack.